Related Experiment Video
Updated: Aug 7, 2025

Author Spotlight: Dendritic Cells Maturation Using Sialidases-Based Enzymatic Treatment of the Cell Surface
Published on: October 20, 2023
MYC-driven synthesis of Siglec ligands is a glycoimmune checkpoint
Benjamin A H Smith1,2, Anja Deutzmann3, Kristina M Correa4
1Sarafan ChEM-H, Stanford University, Stanford, CA 94305.
Abstract:
The Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint receptors that suppress immune cell activation upon engagement of cognate sialoglycan ligands. The cellular drivers underlying Siglec ligand production on cancer cells are poorly understood. We find the MYC oncogene causally regulates Siglec ligand production to enable tumor immune evasion. A combination of glycomics and RNA-sequencing of mouse tumors revealed the MYC oncogene controls expression of the sialyltransferase St6galnac4 and induces a glycan known as disialyl-T. Using in vivo models and primary human leukemias, we find that disialyl-T functions as a "don't eat me" signal by engaging macrophage Siglec-E in mice or the human ortholog Siglec-7, thereby preventing cancer cell clearance. Combined high expression of MYC and ST6GALNAC4 identifies patients with high-risk cancers and reduced tumor myeloid infiltration. MYC therefore regulates glycosylation to enable tumor immune evasion. We conclude that disialyl-T is a glycoimmune checkpoint ligand. Thus, disialyl-T is a candidate for antibody-based checkpoint blockade, and the disialyl-T synthase ST6GALNAC4 is a potential enzyme target for small molecule-mediated immune therapy.
Insights
The MYC oncogene drives cancer immune evasion by controlling the production of disialyl-T, a "don't eat me" signal that engages Siglec receptors on immune cells. This discovery offers new targets for cancer immunotherapy.
Area of Science:
- Immunology
- Glycobiology
- Oncology
Background:
- Siglecs (sialic acid-binding immunoglobulin-like lectins) are glycoimmune checkpoint receptors that inhibit immune cell activation.
- The mechanisms controlling Siglec ligand production on cancer cells, crucial for tumor immune evasion, are not well understood.
Purpose of the Study:
- To investigate the role of the MYC oncogene in regulating Siglec ligand production and its impact on tumor immune evasion.
- To identify the specific glycan ligand and its associated enzymes involved in MYC-driven immune suppression.
Main Methods:
- Glycomics and RNA-sequencing of mouse tumors to analyze gene expression and glycan profiles.
- In vivo mouse models and analysis of primary human leukemias to validate findings.
- Functional assays to assess the interaction between disialyl-T and Siglec receptors.
Main Results:
- The MYC oncogene was found to causally regulate the expression of the sialyltransferase ST6GALNAC4, leading to the production of the disialyl-T glycan.
- Disialyl-T acts as a "don't eat me" signal by binding to macrophage Siglec-E (mouse) or Siglec-7 (human), inhibiting cancer cell clearance.
- High MYC and ST6GALNAC4 expression correlates with high-risk cancers and reduced myeloid cell infiltration in tumors.
Conclusions:
- MYC oncogene regulates cancer cell glycosylation to promote immune evasion by inducing disialyl-T.
- Disialyl-T functions as a glycoimmune checkpoint ligand, making it a potential target for antibody-based therapies.
- ST6GALNAC4, the enzyme synthesizing disialyl-T, is a potential target for small molecule-based immunotherapies.
Related Concept Videos
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Selectins
Cell-surface Signaling

